Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Praxis Precision Medicines Inc (PRAX)

Praxis Precision Medicines Inc (PRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,870,921
  • Shares Outstanding, K 25,007
  • Annual Sales, $ 8,550 K
  • Annual Income, $ -182,820 K
  • EBIT $ -293 M
  • EBITDA $ -298 M
  • 60-Month Beta 2.95
  • Price/Sales 806.17
  • Price/Cash Flow N/A
  • Price/Book 16.99

Options Overview Details

View History
  • Implied Volatility 70.95% (+1.54%)
  • Historical Volatility 107.25%
  • IV Percentile 4%
  • IV Rank 1.85%
  • IV High 241.91% on 02/07/25
  • IV Low 67.73% on 10/22/25
  • Expected Move (DTE 21) 39.06 (14.22%)
  • Put/Call Vol Ratio 4.86
  • Today's Volume 41
  • Volume Avg (30-Day) 606
  • Put/Call OI Ratio 1.27
  • Today's Open Interest 18,386
  • Open Int (30-Day) 21,057
  • Expected Range 235.70 to 313.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -3.00
  • Number of Estimates 8
  • High Estimate -2.17
  • Low Estimate -3.45
  • Prior Year -2.94
  • Growth Rate Est. (year over year) -2.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
171.20 +60.49%
on 12/02/25
286.50 -4.10%
on 12/23/25
+83.91 (+43.96%)
since 11/24/25
3-Month
46.99 +484.72%
on 09/25/25
286.50 -4.10%
on 12/23/25
+225.79 (+461.08%)
since 09/24/25
52-Week
26.70 +929.06%
on 04/09/25
286.50 -4.10%
on 12/23/25
+197.51 (+255.68%)
since 12/24/24

Most Recent Stories

More News
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

PRAX : 274.76 (-0.35%)
Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen  FDA agreed to proposed changes to the EMBRAVE3 trial design to be a single-arm,...

PRAX : 274.76 (-0.35%)
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies

Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures  (p < 0.0002), 66% increase in motor seizure-free days (p = 0.0340), broad and clinically meaningful...

PRAX : 274.76 (-0.35%)
Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming...

PRAX : 274.76 (-0.35%)
Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

PRAX : 274.76 (-0.35%)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

PRAX : 274.76 (-0.35%)
Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting

BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into therapies for central nervous system...

PRAX : 274.76 (-0.35%)
Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

PRAX : 274.76 (-0.35%)
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

PRAX : 274.76 (-0.35%)
Praxis Precision Medicines to Participate in Upcoming Investor Conferences

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

PRAX : 274.76 (-0.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Praxis Precision Medicines Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis Precision Medicines Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 288.96
2nd Resistance Point 284.22
1st Resistance Point 279.49
Last Price 274.76
1st Support Level 270.02
2nd Support Level 265.28
3rd Support Level 260.55

See More

52-Week High 286.50
Last Price 274.76
Fibonacci 61.8% 187.26
Fibonacci 50% 156.60
Fibonacci 38.2% 125.94
52-Week Low 26.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar